Home
/
RELIGION & LIBERTY ONLINE
/
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Jan 1, 2026 1:12 PM

If you suffer from acid reflux, your doctor may prescribe Nexium. But at $9 a pill, the price is enough to give you a worse case of heartburn.

That’s the lowest price in the U.S. If you live in Canada, though, you can get the drug for less than a $1 a pill.

This price disparity leads many politicians to think the solution is obvious: Americans should just buy drugs from Canada or other countries where they are cheaper.

Its plan supported by economic liberals like President Trump and Bernie Sanders. Several years ago Sen. Amy Klobuchar (D-Minn.) and John McCain (R-Az.) twice introduced legislation to allow Americans to order up to a 90-day supply of medicines from a licensed Canadian pharmacy. The Democratic Party even made it a part of their party platform in 2016.

If this seems too easy, it’s because it’s an economically ignorant idea. Writing in the Harvard Business Review a few years ago, Rafi Mohammed explained why this strategy won’t work:

The reason why pharmaceutical prices are relatively high in the U.S. is panies employ mon strategy called differential pricing. This strategy targets specific segments with different prices. So instead of having the same price for everyone, the goal is to tailor the “right” price to various segments. Movie theaters, for instance, use differential pricing by offering lower prices to students and seniors. The assumption is students and seniors are sensitive to price, sooffering targeted discounts to them is profitable. As a result, moviegoers seated next to each other often have paid different prices.

For differential pricing to be profitable, targeted segments have to be easily identifiable, and,most importantly, arbitrage cannot occur. By arbitrage, I mean those who receive discounts don’t resell to customers who are currently paying more. This strategy works well at cinemas: it’s easy to identify seniors/students, and since tickets are sold individually at the door, enterprising seniors/students typically aren’t reselling discounted tickets for a profit.

Why are drug prices so much higher in the U.S.? The answer is straightforward: most countries regulate prices or have a single-payer health care system, in which the government pays for citizens’ health care costs. In a single-payer system, the government buys all a country’s pharmaceuticals, and it has leverage in “take it or leave it” negotiations with panies.

Mohammed’s explanation is helpful, but it’s also plete. What he doesn’t mention is the reason whythe price differential for drugs can work: because expensive medicines in the U.S. subsidize the creation of drugs for the entire world.

According to the pharmaceutical giant Eli Lilly, the average cost to discover and develop a new drug is between $800 million to $1.2 billion, and the average length of time from discovery to patient is 10 to 15 years.

If a product costs $1 billion to produce and bring to market, that is the initial fixed cost. Think of it this way: the initial cost to produce the very first Nexium pill is roughly $1 billion. But once that first pill is created, the cost to produce the second, third, fourth, . . . hundred thousandth pill is very low. But if the initial fixed cost cannot be recovered, then pany will lay out the money and spend a decade or more creating the product. New medications will simply not exist.

This point should be obvious—and yet it is widely overlooked and ignored. People see a drug, like Nexium, and forget that it only exists because a pany believed it could recoup the cost of research and development and make a profit by selling the medicine. But how is pany able to earn back the initial billion dollar fixed costs? By charging some buyer—whether a government, HMO, pany or individual—a price that will cover the initial fixed costs.

Once that fixed costs of creating the drug is covered, though, the price can be reduced since the remaining variable costs (e.g., the cost to produce each individual pill) tend to be relatively low. And this brings us to why you, as an American, pay a higher price for a drug that Canadians and Europeans get much cheaper.

To make it easier to understand, let’s imagine that a medicine is created to cure a single disease in three patients living in America, Canada, and France. Now let’s say that the patient in America pays all of the fixed cost ($1 billion), plus the variable cost for one pill (50 cents), plus 50 cents in profit for pany. In total, the American ends up paying $1,000,000,001 for a single pill.

The pany is happy because they recouped their costs and made a profit (50 cents). Canada and France say that they too want to buy the drug, but they will pay only $1. The pany agrees to sell the pill for $1 to both Canada and France because an additional $1 profit is better than $0 in additional profit. Everyone is happy.

Well, maybe not everyone. The American may say that it wasn’t fair for them to pay all the fixed costs —and they’d be right. In our example, Canada and France are free riders that are able to take advantage of the lower costs only because the Americans have already paid the exorbitant fixed costs. The American subsidized the cost of the drug for the patients in the other countries.

This is exactly what happens with most drugs. Very few new medicines are produced in countries that have government restrictions on drug prices. And almost no new drugs would be produced if all countries had government restrictions on drug prices. Without the willingness of the United States to pay the higher prices, the drugs would never e into existence. Countries like Canada and France are like roommates who let you pay full price for a pizza but expect you to give them a slice in exchange for a few pennies they found in the couch.

Which brings us back to the “reimport the drugs” strategy. The reason this approach won’t work is because once Americans stop subsidizing the drugs for the rest of the world, panies will not be able to recoup their costs for R&D. paniessimply won’t be able to afford to create innovative new medicines. That makes everyone worse off than before.

Ultimately, socialized medicine—in the form of government-imposed drug pricing—doesn’t work for the same reason Margaret Thatcher said socialist governments don’t work: “They always run out of other people’s money.”

Comments
Welcome to mreligion comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
RELIGION & LIBERTY ONLINE
Mandating Monolithic Medicine
Among the warnings sounded as the Democratic health care reform bill was being debated was that the federal insurance mandate included in the bill—even though not national health care per se—would essentially give the federal government control of the insurance industry. The reason: If everyone is forced to buy insurance, then the government must deem what sort of insurance qualifies as adequate to meet the mandate. This piece of Obamacare promises to turn every medical procedure into a major political...
Acton On Tap: Art, Patrimony, and Cultural Investment
If you couldn’t make it to Derby Station in East Grand Rapids last night, there are a couple of things you should know. First of all, you missed a great event and some good conversation. Secondly, you need not worry: we recorded it, and you can listen to David Michael Phelps’ presentation on Art, Patrimony, and Cultural Investment via the audio player below. The bad news is that I was planning to post a little video clip for your enjoyment,...
Samuel Gregg: Benedict’s Creative Minority
This week’s mentary from Research Director Samuel Gregg. Sign up for Acton News & Commentary here. +++++++++ Benedict’s Creative Minority By Samuel Gregg In the wake of Benedict XVI’s recent trip to Britain, we have witnessed—yet again—most journalists’ inability to read this pontificate accurately. Whether it was Queen Elizabeth’s gracious ing address, Prime Minister David Cameron’s sensible reflections, or the tens of thousands of happy faces of all ages and colors who came to see Benedict in Scotland and England...
Work as if It Mattered
The conversations over the last few weeks here on work have raised a couple of questions. In the context of criticisms on the perspectives on work articulated by Lester DeKoster and defended by menter John E. asks, “…what is it that you hope readers will change in their lives, and why?” I want to change people’s view of their work. I want them to see how it has value not simply as a means to some other end, but in...
Explaining the New Democratic Logo
“The new Democratic logo is so bad that the intellectual rot in the official announcement went largely unnoticed.” The rest of my piece is here at The American Spectator. ...
Rev. Sirico: Respect others’ rights, but also their values
A new column by Rev. Robert A. Sirico, president and co-founder of the Acton Institute, was published today in the Detroit News. This column will also be linked in tomorrow’s Acton News & Commentary. Sign up for the free weekly Acton newsletter here. +++++++++ Faith and policy: Respect others’ rights, but also their values FATHER ROBERT SIRICO If such an award were to be given for the Most Contentious Religious Story of 2010, the two main contenders would undoubtedly be...
Trailer: Doing the Right Thing
The Colson Center for Christian Worldview is preparing to release a new study DVD this fall titled, Doing the Right Thing: A Six-Part Exploration of Ethics. The DVD is designed as a resource for small-group studies and features leading thinkers who explore the need for ethical behavior in the marketplace, public square, political life and other areas. Hosts Brit Hume, Chuck Colson, Dr. Robert George and a distinguished panel — including Acton’s Rev. Robert Sirico and Michael Miller — undertake...
Questions on Work and Intellectual Development
Carl Trueman has a lengthy reflection and asks some pertinent and pressing questions on the nature of work and human intellectual development. Recalling his job at a factory as a young man in the 1980s, Trueman writes concerning those who were still at their positions on the line when he had moved on: Their work possessed no intrinsic dignity: it was unskilled, repetitive, poorly paid, and provided no sense of achievement. Yes, it gave them a wage; but not a...
The Daily Show Takes on a Union
The Daily Show exposes some union hypocrisy (HT). In the words of the union local head, es down to greed”: ...
Radio Free Acton: The Stewardship of Art, Part 2
Last week, we posted part 1 of our podcast on the proper Christian stewardship of art; for those who have been waiting for the conclusion, we’re happy to present part 2. David Michael Phelps continues to lead the discussion between Professors Nathan Jacobs and Calvin Seerveld, who previously debated this topic in the Controversy section of our Journal of Markets & Morality. The first portion of that exchange is available at the link for part 1; the remainder of the...
Related Classification
Copyright 2023-2026 - www.mreligion.com All Rights Reserved